ABBV Stock: Price, Earnings History and SEC Filings
AbbVie Inc. (ABBV) last traded at $294.89, up 1.41% on the latest session and up 12.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $3.65 against an analyst estimate of $3.64, a beat of 0.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ABBV earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 31, 2026 | $3.65 | $3.64 | +0.27% |
| Mar 2026 | Apr 29, 2026 | $2.65 | $2.62 | +1.15% |
| Dec 2025 | Feb 4, 2026 | $2.71 | $2.66 | +1.88% |
| Sep 2025 | Oct 31, 2025 | $1.86 | $1.77 | +5.08% |
ABBV beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How ABBV reacts to earnings
Across its last 8 earnings releases, ABBV moved 2.0% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-30 | Before open | +1.41% |
| 2026-10-05 | After close | +0.35% |
| 2026-07-31 | Before open | -2.51% |
| 2026-07-06 | After close | -0.04% |
| 2026-04-29 | Before open | +3.14% |
| 2026-04-03 | After close | -1.03% |
| 2026-02-04 | Before open | -3.79% |
| 2026-01-07 | After close | -3.98% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ABBV financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $61.2B | $4.2B | $17.8B | 6.9% | $2.36 |
| 2024 | $56.3B | $4.3B | $17.8B | 7.6% | $2.39 |
| 2023 | $54.3B | $4.9B | $22.1B | 9.0% | $2.72 |
| 2022 | $58.1B | $11.8B | $24.2B | 20.4% | $6.63 |
| 2021 | $56.2B | $11.5B | $22.0B | 20.5% | $6.45 |
| 2020 | $45.8B | $4.6B | $16.8B | 10.1% | $2.72 |
| 2019 | $33.3B | $7.9B | $12.8B | 23.7% | $5.28 |
| 2018 | $32.8B | $5.7B | $12.8B | 17.4% | $3.66 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ABBV
- 8-K · Oct 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 15, 2026Officer or director change
- 8-K · Oct 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Sep 3, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 18, 2026Other events, Financial statements and exhibits
- 424B5 · Aug 6, 2026
- 8-K · Aug 5, 2026Other events, Financial statements and exhibits
- 424B5 · Aug 4, 2026
- 10-Q · Aug 3, 2026
- 8-K · Jul 31, 2026Results of operations, Financial statements and exhibits
Insider filing activity
ABBV insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ABBV news
- 5 Most Undervalued Dividend Growth Stocks According to Hedge FundsNov 1, 2026 · finance.yahoo.com
- AbbVie Stock Hits a Record After a 5.2% Dividend Raise: Why Its 276% Payout Ratio Doesn’t Tell the Entire StoryNov 1, 2026 · tikr.com
- AbbVie: 3 Key Takeaways for Long-Term InvestorsOct 31, 2026 · fool.com
- Is AbbVie a Buy After Its Latest Earnings Report?Oct 31, 2026 · fool.com
- Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?Oct 31, 2026 · finance.yahoo.com
- AbbVie (ABBV) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats AgainOct 30, 2026 · finance.yahoo.com
- Q3 earnings round-up: AstraZeneca, AbbVie, KenvueOct 30, 2026 · finance.yahoo.com
About AbbVie Inc.
AbbVie Inc. (ABBV) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.